Insider Selling: Stryker Co. (SYK) VP Sells $69,122.40 in Stock

Stryker Co. (NYSE:SYK) VP M Kathryn Fink sold 415 shares of the company’s stock in a transaction on Monday, November 5th. The stock was sold at an average price of $166.56, for a total value of $69,122.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NYSE SYK opened at $171.29 on Friday. Stryker Co. has a 12 month low of $146.80 and a 12 month high of $179.84. The firm has a market capitalization of $62.39 billion, a PE ratio of 26.39, a P/E/G ratio of 2.29 and a beta of 0.64. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.91.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 25th. The medical technology company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.01. Stryker had a return on equity of 28.00% and a net margin of 9.31%. The firm had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.26 billion. As a group, equities analysts anticipate that Stryker Co. will post 7.28 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 31st. Investors of record on Friday, September 28th were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Thursday, September 27th. This represents a $1.88 annualized dividend and a dividend yield of 1.10%. Stryker’s dividend payout ratio (DPR) is presently 28.97%.

Institutional investors have recently added to or reduced their stakes in the stock. MayTech Global Investments LLC boosted its position in shares of Stryker by 9.5% during the second quarter. MayTech Global Investments LLC now owns 18,487 shares of the medical technology company’s stock valued at $3,122,000 after buying an additional 1,604 shares during the last quarter. Chartwell Investment Partners LLC purchased a new stake in shares of Stryker during the second quarter valued at $1,409,000. Arrow Financial Corp boosted its position in shares of Stryker by 3.5% during the third quarter. Arrow Financial Corp now owns 26,549 shares of the medical technology company’s stock valued at $4,716,000 after buying an additional 906 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its position in shares of Stryker by 1.4% during the second quarter. Nissay Asset Management Corp Japan ADV now owns 40,024 shares of the medical technology company’s stock valued at $6,758,000 after buying an additional 544 shares during the last quarter. Finally, Atlantic Trust LLC purchased a new stake in shares of Stryker during the second quarter valued at $105,000. 74.71% of the stock is currently owned by institutional investors.

SYK has been the topic of several recent research reports. Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $186.00 price target on the stock in a research note on Tuesday, August 7th. Canaccord Genuity reaffirmed a “buy” rating and issued a $185.00 price target on shares of Stryker in a research note on Wednesday, July 25th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $184.00 price target on shares of Stryker in a research note on Wednesday, July 25th. BTIG Research initiated coverage on Stryker in a research note on Thursday, August 16th. They issued a “buy” rating and a $187.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a research note on Tuesday, September 11th. Seven research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $181.15.

TRADEMARK VIOLATION WARNING: “Insider Selling: Stryker Co. (SYK) VP Sells $69,122.40 in Stock” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://sportsperspectives.com/2018/11/09/insider-selling-stryker-co-syk-vp-sells-69122-40-in-stock.html.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: What is a put option?

Insider Buying and Selling by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply